Translational Pharmaceutics and the Benefits of Real-Time Adaptive Manufacturing
6 / 47 articles displayed
News
We are delighted to be taking part in the MHRA / HRA Combined Ways of Working Pilot and on Friday 22 June 2018 made its first two pilot Phase I submissions.
News
Quotient Sciences announces that it has completed the integration and rebrand of Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K.
News
The collaboration simplifies contracting and delivery by offering clients a single solution for an entire pediatric program, with only one contract and one PPD point of contact. As a result of that structure, the number of handoffs is significantly reduced and the process is much more streamlined, eliminating the delays that often occur when moving from early dosing to later phases.
Acquisition
Quotient Sciences announces it has acquired Pharmaterials, a CDMO based in Reading, UK. The acquisition strengthens and expands Quotient’s formulation and manufacturing services footprint and further supports the growth of Quotient’s Translational Pharmaceutics platform.
News
Quotient Clinical, the drug development services organization, announces its renaming to Quotient Sciences (Quotient), following the acquisitions of Co-Formulate, QS Pharma and SeaView Research. This new identity signifies a global footprint and an extended range of services, and symbolizes the commitment to ensuring a consistent and high-quality experience for customers.
News
Quotient Sciences has signed an agreement with Nuformix Technologies Limited to evaluate the clinical performance of Nuformix’ lead pharmaceutical cocrystal, NXP001, which is based on a currently marketed treatment in the field of oncology supportive care.
